

This article was originally published [here](#)

Yale University has developed the intellectual property behind Anteros and was first licensed by BMS and later authorised to Anteros. BioMotiv CEO Dr Satish Jindal said:
“Anteros Pharmaceuticals

The post [Bristol-Myers Squibb, BioMotiv launch new biotechnology firm Anteros Pharmaceuticals](#) appeared first on [Pharmaceutical Business review](#).